Compare Enveric Biosciences Inc (ENVB) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Abrdn Physical Platinum Shares ETF — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Abrdn Physical Platinum Shares ETF trades at $15.22 (market cap $1.93B). The key difference: Abrdn Physical Platinum Shares ETF is far larger — about 283.8× Enveric Biosciences Inc's market cap, and Abrdn Physical Platinum Shares ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Abrdn Physical Platinum Shares ETF for 42 Days on average.
| ENVB | PPLT | |
|---|---|---|
Market Cap | $6.80M | $1.93B |
Volume | 64,867 | 1,698,523 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $10.80 | $25.23 |
52-Week Low | $1.27 | $13.73 |
Typical Hold Time | 14 Days | 42 Days |
Enterprise Value | -$1.49M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
PPLT, the abrdn Physical Platinum Shares ETF, trades at $14.78, down 4.46% today, reflecting a bearish technical outlook with moving averages and oscillators signaling sell pressure. Recent news highlights platinum's underperformance versus other precious metals, with the term structure in contango suggesting adequate supply. Key financial ratios are unavailable in the provided data, limiting fundamental assessment.
The outlook remains cautious due to weak technical signals and platinum's lag in the metals rally, though historical seasonality may offer contrarian hope. Risks include commodity price volatility and supply-demand dynamics. Investors should await updated financials for a clearer fundamental picture amid current bearish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →
